Identification of T-cell receptors targeting KRAS-mutated human tumors

Cancer Immunology Research

Volumn 4, Issue 3, 2016, Pages 204-214

  Wang, Qiong J ^a   Yu, Zhiya ^a   Griffith, Kayla ^a   Hanada, Ken Ichi ^a   Restifo, Nicholas P ^a   Yang, James C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A ANTIGEN; K RAS PROTEIN; T LYMPHOCYTE RECEPTOR; HLA A11 ANTIGEN; HLA-A*11:01 ANTIGEN; KRAS PROTEIN, HUMAN; LYMPHOCYTE ANTIGEN RECEPTOR; PROTEIN P21;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EPITOPE MAPPING; GENE FREQUENCY; GENE MUTATION; GENETIC ALGORITHM; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; PERIPHERAL LYMPHOCYTE; SURVIVAL; T LYMPHOCYTE; AMINO ACID SEQUENCE; ANIMAL; CANCER TRANSPLANTATION; GENETICS; IMMUNOLOGY; LYMPH NODE; MISSENSE MUTATION; NONOBESE DIABETIC MOUSE; PANCREATIC NEOPLASMS; PATHOLOGY; PHYSIOLOGY; SCID MOUSE; SPLEEN; TRANSGENIC MOUSE; TUMOR CELL LINE;

ADOPTIVE TRANSFER; AMINO ACID SEQUENCE; ANIMALS; CELL LINE, TUMOR; HLA-A11 ANTIGEN; HUMANS; LYMPH NODES; MICE, INBRED NOD; MICE, SCID; MICE, TRANSGENIC; MUTATION, MISSENSE; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTORS, ANTIGEN, T-CELL; SPLEEN;

EID: 84962013275     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-15-0188     Document Type: Article

References (34)

1. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321:1801-6.
2. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005;2:e17.
3. Luo T, Masson K, Jaffe JD, Silkworth W, Ross NT, Scherer CA, et al. STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability. Proc Natl Acad Sci U S A 2012;109:2860-5.
4. Schultz NA, Roslind A, Christensen IJ, Horn T, Hogdall E, Pedersen LN, et al. Frequencies and prognostic role of KRAS and BRAF mutations in patients with localized pancreatic and ampullary adenocarcinomas. Pancreas 2012;41:759-66.
5. Hruban RH, van Mansfeld AD, Offerhaus GJ, van Weering DH, Allison DC, Goodman SN, et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. Astudyof82carcinomas usingacombinationofmutantenriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 1993;143:545-54.
6. Laghi L, Orbetegli O, Bianchi P, Zerbi A, Di Carlo V, Boland CR, et al. Common occurrence of multiple K-RAS mutations in pancreatic cancers with associated precursor lesions and in biliary cancers. Oncogene 2002;21:4301-6.
7. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65.
8. Russo AL, Borger DR, Szymonifka J, Ryan DP, Wo JY, Blaszkowsky LS, et al. Mutational analysis and clinical correlation of metastatic colorectal cancer. Cancer 2014;120:1482-90.
9. Coulie PG, Lehmann F, Lethe B, Herman J, Lurquin C, Andrawiss M, et al. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci U S A 1995;92:7976-80.
10. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014;371:2189-99.
11. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124-8.
12. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011;17:4550-7.
13. Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, et al. Cancer immunotherapy basedonmutation-specific CD4+Tcells ina patient with epithelial cancer. Science 2014;344:641-5.
14. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009;114:535-46.
15. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, SpanerDE, Maric I, et al. B-cell depletion and remissions of malignancy along with cytokineassociated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012;119:2709-20.
16. Robbins PF, Kassim SH, Tran TL, Crystal JS, Morgan RA, Feldman SA, etal. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res 2015;21:1019-27.
17. Cohen CJ, Zheng Z, Bray R, Zhao Y, Sherman LA, Rosenberg SA, et al. Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine antip53 TCR. J Immunol 2005;175:5799-808.
18. Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 2011;19:620-6.
19. Cohen CJ, Zhao Y, Zheng Z, Rosenberg SA, Morgan RA. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res 2006;66:8878-86.
20. Linard B, Bezieau S, Benlalam H, Labarriere N, Guilloux Y, Diez E, et al. A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion. J Immunol 2002;168:4802-8.
21. Gjertsen MK, Saeterdal I, Saeboe-Larssen S, Gaudernack G. HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes. J Mol Med 2003;81:43-50.
22. Kubuschok B, Neumann F, Breit R, Sester M, Schormann C, Wagner C, et al. Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer. Clin Cancer Res 2006;12:1365-72.
23. Lang AH, Drexel H, Geller-Rhomberg S, Stark N, Winder T, Geiger K, et al. Optimized allele-specific real-time PCR assays for the detection of common mutations in KRAS and BRAF. J Mol Diagn 2011;13:23-8.
24. Wang QJ, Hanada K, Robbins PF, Li YF, Yang JC. Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma. Cancer Res 2012;72:6119-29.
25. Lundegaard C, Lamberth K, Harndahl M, Buus S, Lund O, Nielsen M. NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res 2008;36(Web Server issue):W509-12.
26. Parkhurst MR, Joo J, Riley JP, Yu Z, Li Y, Robbins PF, et al. Characterization of genetically modified T-cell receptors that recognize the CEA691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells. Clin Cancer Res 2009;15:169-80.
27. ∗ 0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. J Immunol 2011;186:685-96.
28. Middleton D, Menchaca L, Rood H, Komerofsky R. New allele frequency database: http://www.allelefrequencies.net. Tissue Antigens 2003;61:403-7.
29. Shen Y, Cao D, Li Y, Kulski JK, Shi L, Jiang H, et al. Distribution of HLA-A, -B, and -C alleles and HLA/KIR combinations in Han population in China. J Immunol Res 2014;2014:565296.
30. Toubaji A, Achtar M, Provenzano M, Herrin VE, Behrens R, Hamilton M, et al. Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers. Cancer Immunol Immunother 2008;57:1413-20.
31. Weden S, Klemp M, Gladhaug IP, Moller M, Eriksen JA, Gaudernack G, et al. Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras. Int J Cancer 2011;128:1120-8.
32. Chaft JE, Litvak A, Arcila ME, Patel P, D'Angelo SP, Krug LM, et al. Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation. Clin Lung Cancer 2014;15:405-10.
33. Rahma OE, Hamilton JM, Wojtowicz M, Dakheel O, Bernstein S, Liewehr DJ, et al. The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors. J Translat Med 2014;12:55.
34. Caruana I, Savoldo B, Hoyos V, Weber G, Liu H, Kim ES, et al. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat Med 2015;21:524-9.